PMID- 22572014
OWN - NLM
STAT- MEDLINE
DCOM- 20140702
LR  - 20221207
IS  - 1000-467X (Print)
IS  - 1944-446X (Electronic)
IS  - 1944-446X (Linking)
VI  - 31
IP  - 10
DP  - 2012 Oct
TI  - Relationship between epidermal growth factor receptor gene mutation and copy 
      number in Chinese patients with non-small cell lung cancer.
PG  - 491-9
LID - 10.5732/cjc.011.10409 [doi]
AB  - Epidermal growth factor receptor (EGFR) gene mutation and copy number are useful 
      predictive markers that guide the selection of non-small cell lung cancer (NSCLC) 
      patients for EGFR-targeting therapy. This study aimed to investigate the 
      correlation between EGFR gene mutation and copy number and clinicopathologic 
      characteristics of Chinese patients with NSCLC. NSCLC specimens collected from 
      205 patients between November 2009 and January 2011 were selected to detect EGFR 
      gene mutations with real-time polymerase chain reaction (RT-PCR) and to detect 
      EGFR gene copy number with fluorescence in situ hybridization (FISH). EGFR 
      mutations primarily occurred in females, non-smokers, and patients with 
      adenocarinomas (all P < 0.001). Tissues from 128 (62%) patients were 
      FISH-positive for EGFR, including 37 (18%) with gene amplification and 91 (44%) 
      with high polysomy. EGFR gene mutation was correlated with FISH-positive status 
      (R = 0.340, P < 0.001). Multivariate analysis showed that not smoking (OR = 
      5.910, 95% CI = 2.363-14.779, P < 0.001) and having adenocarcinoma (OR = 0.122, 
      95% CI = 0.026-0.581, P = 0.008) were favorable factors for EGFR gene mutation. 
      These results show a high frequency of EGFR FISH positivity in NSCLC tissues from 
      Chinese patients and a significant relevance between EGFR gene mutations and 
      FISH-positive status. Among the FISH-positive samples, EGFR gene mutation 
      occurred more frequently in samples with gene amplification compared to those 
      with high polysomy, suggesting that EGFR mutation and gene amplification should 
      be used as clinical decision parameters to predict response to EGFR-targeting 
      therapy.
FAU - Zhang, Lan-Jun
AU  - Zhang LJ
AD  - Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, Guangdong, 
      People's Republic of China. zhlanj@mail.sysu.edu.cn
FAU - Cai, Ling
AU  - Cai L
FAU - Li, Zhe
AU  - Li Z
FAU - Wang, Wu-Ping
AU  - Wang WP
FAU - Guo, Kang
AU  - Guo K
FAU - Shao, Jian-Yong
AU  - Shao JY
FAU - Wang, Jun-Ye
AU  - Wang JY
FAU - Yu, Hui
AU  - Yu H
FAU - Rong, Tie-Hua
AU  - Rong TH
LA  - eng
PT  - Journal Article
DEP - 20120508
PL  - England
TA  - Chin J Cancer
JT  - Chinese journal of cancer
JID - 101498232
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Adenocarcinoma/genetics/metabolism
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Asian People/genetics
MH  - Carcinoma, Non-Small-Cell Lung/*genetics/metabolism
MH  - ErbB Receptors/*genetics/metabolism
MH  - Female
MH  - Gene Amplification
MH  - *Gene Dosage
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Lung Neoplasms/*genetics/metabolism
MH  - Male
MH  - Middle Aged
MH  - *Mutation
MH  - Real-Time Polymerase Chain Reaction
MH  - Smoking
PMC - PMC3777451
EDAT- 2012/05/11 06:00
MHDA- 2014/07/06 06:00
PMCR- 2012/10/01
CRDT- 2012/05/11 06:00
PHST- 2012/05/11 06:00 [entrez]
PHST- 2012/05/11 06:00 [pubmed]
PHST- 2014/07/06 06:00 [medline]
PHST- 2012/10/01 00:00 [pmc-release]
AID - cjc.011.10409 [pii]
AID - cjc-31-10-491 [pii]
AID - 10.5732/cjc.011.10409 [doi]
PST - ppublish
SO  - Chin J Cancer. 2012 Oct;31(10):491-9. doi: 10.5732/cjc.011.10409. Epub 2012 May 
      8.